France-based Servier and Oncodesign have agreed to partner on the development of LRRK2 kinase inhibitors in Parkinson’s disease. Servier to be granted an option to exclusively license one or several drug candidates as soon as they are approved to enter Phase I. Planning to fund the entire program. It is reported that Oncodesign will receive an upfront payment of €3M at the signing of the partnership and they could receive up to €320M ($360M), excluding sales royalties.
Based in France and Publicly traded, they have built expertise for anticancer therapies from target to patient. Founded in 1995, they are a biopharmaceutical company that fills in the innovation gaps in the health sector, based on its unique precision medicine platform. They have raised nearly $30 million since inception. They generate approximately $28 million per annum and operate at a small loss. They report about $9.7 million in cash and currently have a market capitalization of $49.7 million. Clearly this Servier deal will infuse potential.
Also based in France, an international pharmaceutical company governed by non-profit foundation, with its headquarters in Suresnes. It operates in ...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).